Clinical trial
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly…
NCT00006263 · NYU Langone Health, Other · Withdrawn
Key facts
| NCT number | NCT00006263 |
|---|---|
| Title | Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma |
| Official title | Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, Both Newly-Diagnosed and Recurrent |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, carboplatin, temozolomide |
| Enrollment | 0 |
| Start date | Nov 1, 1997 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: